Quote this publication Share Print

WAKIX (pitolisant), histamine H3 inverse agonist/antagonist

NEUROLOGY - New medicinal product
Opinions on drugs - Posted on Oct 14 2016

Reason for request

Inclusion

Minor improvement in the management of narcolepsy with or without cataplexy.

  • WAKIX has Marketing Authorisation in the treatment of adults with narcolepsy with or without cataplexy.
  • In a single short-term study, it reduced daytime sleepiness versus placebo without demonstrating non-inferiority versus modafinil.
  • Its efficacy on cataplexy, another characteristic symptom of narcolepsy, was only demonstrated short-term versus placebo in very severe patients.




Actual benefit

Modéré

-


Improvement in actual benefit

IV (mineur)

-


Therapeutic use

-

Contact Us

Évaluation des médicaments